Science News

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress. GSK licensed bepirovirsen from Ionis an...

FRANKFURT, Germany & RALEIGH, N.C.--(BUSINESS WIRE)--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new research at the World Parkinson Congress (WPC) 2026 that uncovers the multifaceted burden of "OFF" episodes in Parkinson's disease (PD). The qualitative literature review demonstrates that these episodes are not only a re-emergence of motor symptoms, but also a complex mix of debilitating motor and non-motor symptoms that impact...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago. The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without...

DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation...

TRUTH OR CONSEQUENCES, N.M.--(BUSINESS WIRE)--In advance of the first flight test of Virgin Galactic’s next generation Spaceship, the company announced today that VSS Unity, its prototype Spaceship, has returned to the skies above Spaceport America in New Mexico for the first of several anticipated glide flights. These flights are designed to prepare the company’s pilots and operations teams ahead of new Spaceship operations. “Unity's glide characteristics and energy-management profile provide...

ST. PAUL, Minn.--(BUSINESS WIRE)--Scott Kirkland, CFO, will address financial analysts at the William Blair Annual Growth Stock Conference on Tuesday June 2, 2026. Ecolab will offer a webcast of Mr. Kirkland’s presentation. Details for the webcast are as follows: TIME: 10:00am CT DATE: June 2, 2026 DURATION: Approximately 30 minutes LOCATION: www.ecolab.com/investor ARCHIVE: A replay of the webcast will be available through September 2, 2026. To access the webcast, visit the Events & Presen...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. Second-quarter GAAP net income was $339 million, or $1.20 per share. This compares with $215 million, or $0.75 per share, in the second quarter of 2025. Non-GAAP net income(3) was $423 million, or $1.49 per share, during the quarter, compar...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences’ Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentat...

COCOA BEACH, Fla. & SEATTLE--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device, today announced a joint venture partnership with Dr. Lyly Fisher, DDS, Diplomate, ABDSM, ASBA -- a dual board-certified sleep dentist with offices in Seattle and Renton, Washington. Dr. Fisher is the first sleep dentist in the Seattle area to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP therapy. Th...

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing. The Serie...